Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide
Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide GlobeNewswire November 07, 2025 Results, presented at ObesityWeek(R) 2025, showed patients receiving NG101 saw 40% reduction in nausea incidence and 67% reduction in vomiting incidence Only 30% of patients who start GLP-1s for weight loss […]